Document Detail

Influence of vessel involvement and early streptokinase therapy on regional and global left ventricular function in acute myocardial infarction.
MedLine Citation:
PMID:  3428844     Owner:  NLM     Status:  MEDLINE    
150 consecutive patients with acute myocardial infarction received 750,000 units of intravenous streptokinase within four hours of pain onset. Angiography was performed on day 6, from which ejection fraction (EF), infarct-related ejection fraction (IREF), and non-infarct related ejection fraction (NREF) were calculated. 50% stenosis was considered to be significant. The streptokinase patients with patent infarct-related arteries who had no evidence of previous myocardial infarction were compared with 82 conventionally treated (without streptokinase) patients who had no evidence of previous myocardial infarction. Sub-group analysis based on vessel involvement, usage and timing of streptokinase was done. Streptokinase was associated with better left ventricular function in all sub-groups if given less than 2 hours after pain onset. In inferior myocardial infarction, streptokinase patients with single-vessel disease had normal EF (67 +/- 8), compared to significantly depressed EF in multi-vessel disease (56 +/- 12, p less than 0.05). This difference is accounted for more by the NREF than the IREF. In anterior infarction, patients with single-vessel disease did only slightly better than multi-vessel disease. In multi- and single-vessel anterior infarction, preservation of function by streptokinase appears to be due to the compensatory ability of the non-infarcted region as well as the residual function of the infarct-related region. region.
D G Fine; S Vinker; A T Weiss; S Welber; D Sapoznikov; C Lotan; M Mosseri; S Rosenheck; Y Hasin; M S Gotsman
Related Documents :
7296554 - Human myocardial morphologic and functional changes in the first 24 hours after doxorub...
1636574 - Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicent...
6488304 - Intravenous versus intracoronary streptokinase for acute transmural myocardial infarction.
8625544 - Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intra...
24326884 - Evaluation of coronary artery disease and cardiac morphology and function in patients w...
20085124 - Atrial fibrillation in pure rheumatic mitral valvular disease is expression of an atria...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Herz     Volume:  12     ISSN:  0340-9937     ISO Abbreviation:  Herz     Publication Date:  1987 Dec 
Date Detail:
Created Date:  1988-03-24     Completed Date:  1988-03-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7801231     Medline TA:  Herz     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  398-404     Citation Subset:  IM    
Department of Cardiology, Hadassah University Hospital, Jerusalem, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiac Output / drug effects
Coronary Circulation / drug effects*
Middle Aged
Myocardial Contraction / drug effects*
Myocardial Infarction / therapy*
Streptokinase / therapeutic use*
Reg. No./Substance:
EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prognostic importance of silent ischemia during long-term follow-up of patients with coronary artery...
Next Document:  Comparative study of mechanical heart valves for implantation in mitral position